CytoDyn Inc. announced encouraging survival outcomes in a group of patients with metastatic triple-negative breast cancer (mTNBC) treated with leronlimab, a CCR5 antagonist. Some patients who had failed prior treatments for metastatic disease survived beyond 36 months, are currently alive, and show no evidence of active disease. Following the resolution of a dispute with its former CRO, CytoDyn accessed follow-up records from patients previously treated with leronlimab in oncology trials. These findings have been summarized and submitted as an abstract to the European Society for Medical Oncology (ESMO) Breast Cancer meeting in May 2025.
This news is potentially impactful for both the oncology field and patients with mTNBC, a particularly aggressive and difficult-to-treat cancer. The observed survival rates, especially in patients who had exhausted other treatment options, suggest that leronlimab may offer a new therapeutic avenue. This is particularly noteworthy given the limited treatment options and generally poor prognosis associated with mTNBC. The apparent lack of significant adverse events associated with leronlimab further strengthens its potential as a viable treatment option.
CytoDyn is initiating two pre-clinical studies investigating potential synergistic effects of leronlimab in combination with sacituzumab govitecan (an antibody-drug conjugate) and pembrolizumab (an immune checkpoint inhibitor). The company is also continuing follow-up testing on the long-term survivors currently demonstrating no evidence of disease.
This development could mark a significant step forward in the treatment of mTNBC. The upcoming presentation at the ESMO Breast Cancer meeting will provide a valuable opportunity for peer review and discussion within the oncology community. The pre-clinical studies focusing on combination therapies hold promise for further enhancing treatment efficacy. The ongoing follow-up of long-term survivors will be crucial to further understanding the long-term effects and potential of leronlimab in mTNBC.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
